Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India

Background: There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial conducted test the efficacy of mild and moderate disease 19 (COVID-19). Methods: A double blind, parallel, randomised, placebo-controlled among adult COVID-19 patients with severity on admission COVID dedicated tertiary healthcare eastern India. Enrolment done between 1st August 31st October 2020. On day 1 post enrolment, intervention arm received 12 mg while non-interventional placebo tablets. Results: About one-fourth (23.6%) one-third (31.6%) were tested reverse transcriptase polymerase chain reaction (RTPCR) negative for SARS-CoV-2 6th day. Although this difference found be statistically insignificant [rate ratio (RR): 0.8; 95% confidence interval (CI): 0.4-1.4; p=0.348]. All group successfully discharged. In comparison same observed 93%. significant (RR: 1.1; CI; 1.0-1.2; p=0.045). Conclusions: Inclusion treatment regimen could not said certainty based our study results as had shown only marginal benefit successful discharge from hospital no other benefits.